Similar articles

• Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies.

  Wright AD, Dodson PM. Wright AD, et al. Eye (Lond). 2011 Jul;25(7):843-9. doi: 10.1038/eye.2011.62. Epub 2011 Mar 25. Eye (Lond). 2011. PMID: 21436845 Free PMC article. Review.
• Effects of medical therapies on retinopathy progression in type 2 diabetes.

  ACCORD Study Group; ACCORD Eye Study Group; Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ. ACCORD Study Group, et al. N Engl J Med. 2010 Jul 15;363(3):233-44. doi: 10.1056/NEJMoa1001288. Epub 2010 Jun 29. N Engl J Med. 2010. PMID: 20587587 Free PMC article. Clinical Trial.
• Retinopathy progression in type 2 diabetes.

  Baum SJ. Baum SJ. N Engl J Med. 2010 Nov 25;363(22):2172; author reply 2173-4. doi: 10.1056/NEJMc1009236. N Engl J Med. 2010. PMID: 21105808 No abstract available.
• Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.

  Mottl AK, Buse JB, Ismail-Beigi F, Sigal RJ, Pedley CF, Papademetriou V, Simmons DL, Katz L, Mychaleckyj JC, Craven TE. Mottl AK, et al. Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1693-1702. doi: 10.2215/CJN.06200518. Epub 2018 Oct 25. Clin J Am Soc Nephrol. 2018. PMID: 30361335 Free PMC article. Clinical Trial.
• Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus.

  Otsuki M, Goya K, Kasayama S. Otsuki M, et al. Vasc Health Risk Manag. 2005;1(3):209-15. Vasc Health Risk Manag. 2005. PMID: 17319106 Free PMC article. Review.